68.00
-4.36%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Puriblood Medical Co
Its shares trade on Taipei Exchange under the ticker 6847.TWO. It has been listed since 5 November 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 82.3m and a net loss of TWD 39.0m. At that date it held total assets of TWD 236.7m and shareholders' equity of TWD 140.2m.
Puriblood Medical Co., Ltd. developed a technology for blood cell separation that is supported by a research center R&D center for membrane technology RDCMT. The company is headquartered in Baoshan, Hsinchu. The company went IPO on 2021-11-05. The firm mainly develops blood purification-related medical equipment. The products include anti-blood-type leukocyte reduction filters for blood transfusion, which are used to reduce the number of white blood cells in red blood cell concentrates to reduce transfusion reactions; animal blood filters, which are used to reduce the number of white blood cells in animal blood to reduce transfusion reactions; animal blood bags, which are used to store blood; micro filters, which are used to remove interference from human cell signals or the number of white blood cells.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 5 Nov 2021
- Website
- puriblood.com/en ↗
Leadership
Pay as last reported
- Yanwen ChenChairman of the Board, General Manager, Acting Deputy General Manager-Operation Management Center, since 2024
- Xiaowen Fan JiangHead of Finance & Accounting, Corporate Governance Officer
- Chengqi LianDirector
- Xiujuan GuoIndependent Director
- Mr. Shaofeng JianIndependent Director
- Zhiyuan LuIndependent Director
- Weiyun SunIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Puriblood Medical's RDCMT research center supports membrane technology development for blood cell separation.
- Anti-blood-type leukocyte reduction filters reduce transfusion reactions in blood transfusions.
- Animal blood filters and blood bags are used for animal blood transfusion and storage.
Weaknesses
- The company is headquartered in Baoshan, Hsinchu, which may limit local market access.
- Puriblood Medical's IPO was on 5 November 2021, indicating a relatively new market presence.
- The company focuses on blood purification equipment, which may limit diversification.
Opportunities
- Expanding into the Health Care sector in Taiwan for blood purification equipment.
- Growing demand for animal blood filters in veterinary medicine and research.
- Increasing use of micro filters for human cell signal interference removal.
Threats
- Competition from established Health Care companies in Taiwan's market.
- Regulatory changes in the Health Care industry could affect product approvals.
- Dependence on membrane technology RDCMT for innovation may pose risks.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.